Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


March 27, 2015 4:39 AM ET

Biotechnology

Company Overview of Cibus Global, Ltd.

Company Overview

Cibus Global, Ltd. develops precision gene editing systems for agricultural, industrial, and human health markets worldwide. It focuses on the development of industrial biotechnology, agriculture, and human health and wellness solutions by using Rapid Trait Development System (RTDS), a precision gene editing technology that is used to develop new and beneficial characteristics by modifying cell function. The company, through its subsidiary, offers Squalane, an oil compound that is used in cosmetics, pharmaceuticals, and specialty lubricants; and Ergosterol, a natural sterol that is found in yeast and fungal species. Its RTDS technology is used in various applications, including the optimizat...

6455 Nancy Ridge Drive

Suite 100

San Diego, CA 92121

United States

Founded in 2001

Phone:

858-450-0008

Key Executives for Cibus Global, Ltd.

Chief Executive Officer and President
Senior Vice President, Chief Executive Officer of Nucelis and President of Nucelis
Senior Vice President of Research & Development
Head of the Cell Biology Department
Vice President of International Development
Compensation as of Fiscal Year 2014.

Cibus Global, Ltd. Key Developments

Cibus and Rotam Announce Launch of its First Non-Transgenic Commercial Product

Cibus Global and Rotam have announced the launch of non-transgenic SU Canola(TM) (Sulfonylurea Tolerant) in the United States. Rotam has developed two new effective weed control solutions specifically designed for use on SU Canola(TM). SU Canola offers farmers a new alternative for weed control in canola that will provide sound stewardship options to deal with the management of glyphosate weed resistance. SU Canola is an optimal fit for rotation with glyphosate tolerant soybeans reducing weed pressure caused by volunteer glyphosate tolerant canola in soybean fields. Farmers can anticipate a product that has been developed to include exceptional broadleaf weed control, excellent crop safety, in an economical and easy-to-use package. Additionally, many participants in the canola industry including processors, farmers, and end use food consumers, will benefit from SU Canola as the oil and meal derived from this canola will address the growing demand for non-transgenic food ingredients. This initiative combines years of Cibus' cutting-edge laboratory research with Rotam's strong manufacturing and production capabilities in bringing two sulfonylurea herbicide products exclusively registered for SU Canola: Draft(TM), designed for Midwest applications, and Cleat(TM), registered for use in California. "Rotam is thrilled to join Cibus and provide a new system featuring its herbicide solutions for canola farmers," said Steve Stansell, Marketing Manager, Rotam North America.

Cibus Global Announces Executive Changes

Keith Walker, Ph.D., who has led Cibus Global since the company was founded in 2001, has announced his retirement. Rapid Trait Development System developer, and company's Sr. VP of Research and Development Peter Beetham has been tapped to take the top position at the precision gene editing firm. Walker has been named to the Cibus Board of Directors. Dr. Beetham has led the development of the company's core technologies in gene editing that have driven the company's expansion to more than 100 employees with over 70 scientists focusing on advancing company's patented and gene editing technologies. Greg Gocal, Ph.D., the current Vice President of Research at the company, also a member of the founding group has been promoted to Senior Vice President of Research and Development to oversee all research activities at the company. Dr. Gocal, prior to joining the company held research positions and headed the molecular biology group at Valigen.

Cibus Global Appoints Keith Walker as CEO and President

Cibus Global announced that Keith Walker, Ph.D., has been appointed as CEO and President. Dr. Walker has held the position of President since the company was founded in 2001. Prior to Cibus, Dr. Walker held a variety of management positions at the Mycogen Corporation, ranging from business development, biotechnology research management and technology in-and-out-licensing.

Similar Private Companies By Industry

Company Name Region
Envisia Therapeutics Inc. United States
3-D Matrix, Inc. United States
Cellicon Biotechnologies, Inc. United States
JR Scientific, Inc. United States
Rinat Neuroscience Corporation United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
May 16, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Cibus Global, Ltd., please visit www.cibus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.